Tests Find Missing Ingredients in Familiar Medicines
Seven samples carrying the names of six widely used medicine brands have been declared counterfeit by the Sindh Drug Testing Laboratory in Karachi after testing failed to identify their expected active ingredients. The findings cover Augmentin, Velosef, No-Spa Forte, Mucaine, Brexin and two batches of Laxoberon liquid.
Contents
The findings, reported on October 25, 2026, concern medicines used for bacterial infections, stomach acidity, muscle spasms, pain and constipation. Among the products identified were Velosef 500mg capsules bearing batch number LX3A, Augmentin tablets bearing batch number YT9D, Brexin tablets bearing batch number W6BC, and Laxoberon liquid bearing batch numbers 46292 and 43445.
Syed Adnan Rizvi, director of the Sindh Drug Testing Laboratory, said the medicines had been classified as counterfeit under the Drugs Act, 1976. The laboratory sent its findings to the secretary of the Sindh Quality Control Board and the Provincial Drug Inspector for Karachi South for further action.
Manufacturers associated with the affected brands denied producing the identified batches. Martin Dow Marker, the manufacturer associated with Laxoberon, also notified authorities in writing that the two batches carrying its product name had not been made by the company.
The findings put two practical tasks before regulators: identifying where the counterfeit products came from and preventing more packs from reaching patients. Authorities had not publicly identified their source, distribution network or the people responsible. The published details also left some product identifiers incomplete, making the exact medicine name, strength and batch number particularly important when checking a pack.
Which Products Failed the Tests?
The laboratory findings describe failures to identify the substances that should make each medicine work. An active ingredient is the part of a medicine that produces its intended treatment effect. Packaging, a familiar brand name and a printed strength can look reassuring, while laboratory testing examines what the sample actually contains.
- Augmentin tablets: the laboratory account identifies a strength of 625mg and says neither amoxicillin nor clavulanic acid was identified. Batch YT9D was named in another description, which listed the strength as 526mg.
- Velosef 500mg capsules: batch LX3A was identified, and testing failed to identify cephradine, the expected antibiotic ingredient.
- No-Spa Forte 80mg tablets: testing failed to identify drotaverine hydrochloride, the ingredient used to relieve muscle spasms.
- Mucaine suspension: none of the three expected active ingredients was identified. Another description of the findings called the product Mycon Suspension.
- Brexin tablets: batch W6BC was identified, and testing failed to identify piroxicam, the expected ingredient used for pain and inflammation.
- Laxoberon liquid: batches 46292 and 43445 were identified, and testing failed to identify sodium picosulphate, the expected laxative ingredient.
The Augmentin strength and the Mucaine product name therefore need confirmation against the laboratory records or a regulator's product notice. Accurate identification matters because a patient or pharmacist needs to match the warning to a particular pack.
The count of seven comes from six medicine brands, with two different Laxoberon batches included. Most of the other products account for one sample each. A batch number identifies a particular production group and gives inspectors a more precise way to trace stock than a brand name alone.
Why Missing Ingredients Matter to Patients
Augmentin and Velosef are antibiotics. A patient taking a counterfeit product without the expected antibiotic may receive no effective treatment from that product while an infection continues. Someone who believes treatment has already started may also delay seeking another medical assessment.
No-Spa Forte, Mucaine, Brexin and Laxoberon serve different purposes, but the immediate problem is similar: the expected medicine may fail to relieve the condition for which it was taken. Pain, muscle spasms, stomach discomfort or constipation may continue, leaving the patient without the intended benefit.
Amoxicillin and clavulanic acid work together in genuine Augmentin. Amoxicillin acts against susceptible bacteria, while clavulanic acid helps protect it from certain substances bacteria produce to resist treatment. Failure to identify both ingredients in the tested sample leaves the patient without that intended combination.
Patients checking a medicine need the details printed on its packaging, including the name, strength and batch number. A pharmacist or prescribing clinician can help assess a suspected pack and arrange appropriate treatment. For someone already feeling worse, obtaining medical care is more urgent than waiting for a supply investigation to finish.
Manufacturers Disown the Identified Batches
Martin Dow Marker's written notification gives investigators a specific point to pursue in the Laxoberon findings. The company told authorities that batches 46292 and 43445 were not produced by it, despite appearing under the name of a medicine associated with the manufacturer.
Manufacturers linked to the other affected brands also denied making the specified batches. Those responses place the investigation on products circulating under recognised company and brand names, with laboratory findings showing that the tested samples lacked their expected ingredients.
Inspectors now face a tracing problem as well as a testing problem. They need to connect the sampled packs to sellers, suppliers and any records showing how the products entered distribution. Batch markings and packaging can help organise that work, while the manufacturers' responses provide information to compare with the physical products.
For pharmacies and medicine distributors, the practical consequence is a need to check the precise stock identified in regulatory notices. For patients, the familiar appearance of a package makes access to accurate batch information especially valuable.
A Separate DRAP Alert Covers Five Batches
The Drug Regulatory Authority of Pakistan, known as DRAP, also issued a rapid alert concerning five counterfeit medicine batches detected in Karachi. Acting on information from Sindh drug authorities and laboratory findings, it directed provincial drug control authorities and field enforcement teams to seize the identified products.
The five products named in that alert were Mucaine syrup, Augmentin tablets, Velosef capsules, Nezomist nasal spray and No-Spa Forte 80mg tablets. The alert identified Nezomist batch FW 099 and No-Spa Forte batch AN010. Testing failed to verify the identity of the expected active ingredients in the five samples.
DRAP said the products had allegedly been manufactured illegally and supplied to the market under the names of established pharmaceutical brands. The authority warned that their quality, safety and therapeutic effectiveness could not be established and that using them could potentially be life threatening.
The five batches in the DRAP alert and the seven samples in the Sindh laboratory findings are different counts covering different product lists. The alert includes Nezomist, while the seven sample findings include Brexin and two Laxoberon batches. Their relationship has not been publicly clarified, so patients and sellers need to follow the identifiers attached to each notice.
What Regulators Have Done So Far
The laboratory classification and DRAP's seizure directions represent different stages of the response. The laboratory examined the samples and classified them under the Drugs Act, 1976. Drug inspectors and regulatory authorities are responsible for acting on those findings in the medicine market.
The sequence described publicly is:
- The Sindh Drug Testing Laboratory examined samples carrying six medicine brand names and failed to identify their expected active ingredients.
- The laboratory classified seven samples as counterfeit under the Drugs Act, 1976, and forwarded its reports to the Sindh Quality Control Board secretary and the Karachi South drug inspector.
- Manufacturers denied making the identified batches, with Martin Dow Marker providing a written response concerning two Laxoberon batches.
- DRAP issued a separate rapid alert covering five batches and instructed provincial authorities and enforcement teams to seize the identified products.
- The seven sample findings were reported on October 25, 2026; dates for sampling, testing and subsequent enforcement were not specified.
No next hearing, enforcement deadline or scheduled public update was announced. The immediate regulatory work is to locate the identified stock, prevent further distribution and trace the supply routes behind it.
The Details Needed to Protect Buyers
Batch numbers are among the most useful details in these findings because medicine warnings often concern particular stock. Velosef LX3A, Brexin W6BC and Laxoberon 46292 and 43445 provide concrete identifiers for checks. Augmentin YT9D also provides an identifier, alongside the strength discrepancy that requires confirmation.
No-Spa Forte AN010 and Nezomist FW 099 belong to the five batch DRAP alert. Keeping those identifiers with that alert preserves the connection between each product and the action ordered by the regulator.
Patients who suspect a pack should retain its packaging and purchase details for a pharmacist, clinician or drug inspector to examine. Anyone relying on an antibiotic or another prescribed medicine should seek prompt professional advice about continuing effective treatment. The investigation's most immediate purpose is to stop counterfeit stock reaching more people while patients receive medicines that contain the ingredients they need.
Key Points
- Sindh's laboratory declared seven samples carrying six medicine brand names counterfeit after failing to identify their expected active ingredients.
- The findings cover Augmentin, Velosef, No-Spa Forte, Mucaine, Brexin and two Laxoberon batches.
- Manufacturers denied making the identified batches; Martin Dow Marker submitted a written denial concerning Laxoberon batches 46292 and 43445.
- Laboratory reports were sent to the Sindh Quality Control Board secretary and the Karachi South drug inspector for further action.
- A separate DRAP alert ordered seizure of five batches, including Nezomist FW 099 and No-Spa Forte AN010.
- The source of the counterfeit products and the people responsible had not been publicly identified.
